| __timestamp | Galapagos NV | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 111110000 | 55430000 |
| Thursday, January 1, 2015 | 129714000 | 65510000 |
| Friday, January 1, 2016 | 139574000 | 71160000 |
| Sunday, January 1, 2017 | 218502000 | 70644000 |
| Monday, January 1, 2018 | 322876000 | 70418000 |
| Tuesday, January 1, 2019 | 427320000 | 63238000 |
| Wednesday, January 1, 2020 | 523667000 | 59777000 |
| Friday, January 1, 2021 | 491707000 | 60152000 |
| Saturday, January 1, 2022 | 515083000 | 54540000 |
| Sunday, January 1, 2023 | 241294000 | 52243000 |
| Monday, January 1, 2024 | 64536000 |
Data in motion
In the ever-evolving pharmaceutical industry, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Galapagos NV has consistently outpaced Taro Pharmaceutical Industries Ltd. in R&D investment. From 2014 to 2023, Galapagos NV's R&D expenses surged by over 300%, peaking in 2020 with a remarkable 523 million USD. In contrast, Taro's R&D spending remained relatively stable, with a modest increase of around 16% over the same period.
This disparity highlights Galapagos NV's aggressive pursuit of new drug development, while Taro maintains a more conservative approach. Interestingly, 2023 saw a significant drop in Galapagos NV's R&D spending, possibly indicating a strategic shift or external challenges. As we look to the future, these trends offer valuable insights into the strategic priorities of these pharmaceutical giants.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Galapagos NV
Comparing Innovation Spending: Biogen Inc. and Galapagos NV
Research and Development Expenses Breakdown: Incyte Corporation vs Taro Pharmaceutical Industries Ltd.
R&D Spending Showdown: Exelixis, Inc. vs Taro Pharmaceutical Industries Ltd.
R&D Insights: How Jazz Pharmaceuticals plc and Taro Pharmaceutical Industries Ltd. Allocate Funds
Research and Development Expenses Breakdown: Pharming Group N.V. vs Taro Pharmaceutical Industries Ltd.
Research and Development Investment: Grifols, S.A. vs Taro Pharmaceutical Industries Ltd.
Who Prioritizes Innovation? R&D Spending Compared for Alpine Immune Sciences, Inc. and Galapagos NV
Analyzing R&D Budgets: Amneal Pharmaceuticals, Inc. vs Galapagos NV
CRISPR Therapeutics AG vs Galapagos NV: Strategic Focus on R&D Spending
R&D Insights: How MannKind Corporation and Taro Pharmaceutical Industries Ltd. Allocate Funds
Taro Pharmaceutical Industries Ltd. vs Galapagos NV: Efficiency in Cost of Revenue Explored